CompletedNCT02225106
Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI
It focuses on ADHD and currently lists study information in the United States.
ADHD, Cognition Disorder, ...DrugFrom 18 Years to 55 Years
Understand this study
Who was this study for?
Listed age limits: 18 years to 55 years.
- Listed locations
- Bethesda, United StatesSee all locations and recruitment
Compensation and expense reimbursement have not been verified for this summary.
Study information
Study start dateStarted: August 6, 2014
- Recruitment status
- Completed
- Enrollment listed in the registry
- 11
- Sponsor
- University of Pennsylvania
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT02225106
- Official title
- Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI
Recruitment & locations
CompletedBethesda
Questions about this study
Who is behind this study?
The study sponsor is University of Pennsylvania, a university.
Did this study involve medication?
Yes. The study involved medication, including Methylphenidate.
Who was this study for?
Listed age limits: 18 years to 55 years.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedNCT02059642
MG01CI 1400 mg Compared With Placebo for ADHD
This study is completed in the United States and in Israel. It is testing MG01CI 1400 mg Compared With Placebo for ADHD.
CompletedNCT00500149
Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) for ADHD
This study is completed in the United States. It is testing time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) for ADHD.
CompletedNCT02555150
A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD
This study is completed. It focuses on ADHD and currently lists study information in the United States.